We evaluated the potential of cardiovascular-disease-associated microRNAs to predict in the early stages of gestation (from 10 to 13 gestational weeks) the occurrence of a miscarriage or stillbirth. The gene expressions of 29 microRNAs were studied retrospectively in peripheral venous blood samples derived from singleton Caucasian pregnancies diagnosed with miscarriage (n = 77 cases; early onset, n = 43 cases; late onset, n = 34 cases) or stillbirth (n = 24 cases; early onset, n = 13 cases; late onset, n = 8 cases; term onset, n = 3 cases) and 80 selected gestational-age-matched controls (normal term pregnancies) using real-time RT-PCR. Altered expressions of nine microRNAs (upregulation of miR-1-3p, miR-16-5p, miR-17-5p, miR-26a-5p, miR-146a-5p, and miR-181a-5p and downregulation of miR-130b-3p, miR-342-3p, and miR-574-3p) were observed in pregnancies with the occurrence of a miscarriage or stillbirth. The screening based on the combination of these nine microRNA biomarkers revealed 99.01% cases at a 10.0% false positive rate (FPR). The predictive model for miscarriage only was based on the altered gene expressions of eight microRNA biomarkers (upregulation of miR-1-3p, miR-16-5p, miR-17-5p, miR-26a-5p, miR-146a-5p, and miR-181a-5p and downregulation of miR-130b-3p and miR-195-5p). It was able to identify 80.52% cases at a 10.0% FPR. Highly efficient early identification of later occurrences of stillbirth was achieved via the combination of eleven microRNA biomarkers (upregulation of miR-1-3p, miR-16-5p, miR-17-5p, miR-20a-5p, miR-146a-5p, and miR-181a-5p and downregulation of miR-130b-3p, miR-145-5p, miR-210-3p, miR-342-3p, and miR-574-3p) or, alternatively, by the combination of just two upregulated microRNA biomarkers (miR-1-3p and miR-181a-5p). The predictive power achieved 95.83% cases at a 10.0% FPR and, alternatively, 91.67% cases at a 10.0% FPR. The models based on the combination of selected cardiovascular-disease-associated microRNAs had very high predictive potential for miscarriages or stillbirths and may be implemented in routine first-trimester screening programs.

Department of Molecular Biology and Cell Pathology 3rd Faculty of Medicine Charles University 14700 Prague Czech Republic

Institute for the Care of the Mother and Child 3rd Faculty of Medicine Charles University 14700 Prague Czech Republic

Zobrazit více v PubMed

Robinson G.E. Pregnancy loss. Best. Pract. Res. Clin. Obstet. Gynaecol. 2014;28:169–178. doi: 10.1016/j.bpobgyn.2013.08.012. PubMed DOI

Savitz D.A., Hertz-Picciotto I., Poole C., Olshan A.F. Epidemiologic measures of the course and outcome of pregnancy. Epidemiol. Rev. 2002;24:91–101. doi: 10.1093/epirev/mxf006. PubMed DOI

DeVilbiss E.A., Mumford S.L., Sjaarda L.A., Connell M.T., Plowden T.C., Andriessen V.C., Perkins N.J., Hill M.J., Silver R.M., Schisterman E.F. Prediction of pregnancy loss by early first trimester ultrasound characteristics. Am. J. Obstet. Gynecol. 2020;223:242.e1–242.e22. doi: 10.1016/j.ajog.2020.02.025. PubMed DOI PMC

Practice Committee of the American Society for Reproductive Medicine Evaluation and treatment of recurrent pregnancy loss: A committee opinion. Fertil. Steril. 2012;98:1103–1111. doi: 10.1016/j.fertnstert.2012.06.048. PubMed DOI

Linnakaari R., Helle N., Mentula M., Bloigu A., Gissler M., Heikinheimo O., Niinimäki M. Trends in the incidence, rate and treatment of miscarriage-nationwide register-study in Finland, 1998–2016. Hum. Reprod. 2019;34:2120–2128. doi: 10.1093/humrep/dez211. PubMed DOI

Makrydimas G., Sebire N.J., Lolis D., Vlassis N., Nicolaides K.H. Fetal loss following ultrasound diagnosis of a live fetus at 6–10 weeks of gestation. Ultrasound Obstet. Gynecol. 2003;22:368–372. doi: 10.1002/uog.204. PubMed DOI

American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Gynecology ACOG Practice Bulletin No. 200: Early Pregnancy Loss. Obstet. Gynecol. 2018;132:e197–e207. doi: 10.1097/AOG.0000000000002899. PubMed DOI

Redinger A., Nguyen H. StatPearls [Internet] StatPearls Publishing; Treasure Island, FL, USA: 2022. Incomplete Abortions. PubMed

Kim C., Barnard S., Neilson J.P., Hickey M., Vazquez J.C., Dou L. Medical treatments for incomplete miscarriage. Cochrane Database Syst. Rev. 2017;1:CD007223. doi: 10.1002/14651858.CD007223.pub4. PubMed DOI PMC

Bjørn A.M., Nielsen R.B., Nørgaard M., Nohr E.A., Ehrenstein V. Risk of miscarriage among users of corticosteroid hormones: A population-based nested case-control study. Clin. Epidemiol. 2013;5:287–294. doi: 10.2147/CLEP.S46893. PubMed DOI PMC

Larsen E.C., Christiansen O.B., Kolte A.M., Macklon N. New insights into mechanisms behind miscarriage. BMC Med. 2013;11:154. doi: 10.1186/1741-7015-11-154. PubMed DOI PMC

Michels T.C., Tiu A.Y. Second trimester pregnancy loss. Am. Fam. Physician. 2007;76:1341–1346. PubMed

American College of Obstetricians and Gynecologists ACOG practice bulletin. Management of recurrent pregnancy loss. (Replaces Technical Bulletin Number 212, September 1995). American College of Obstetricians and Gynecologists. Int. J. Gynaecol. Obstet. 2002;78:179–190. PubMed

ESHRE Guideline Group on RPL. Bender Atik R., Christiansen O.B., Elson J., Kolte A.M., Lewis S., Middeldorp S., Mcheik S., Peramo B., Quenby S., et al. ESHRE guideline: Recurrent pregnancy loss: An update in 2022. Hum. Reprod. Open. 2023;2023:hoad002. PubMed PMC

Christiansen O.B., Steffensen R., Nielsen H.S., Varming K. Multifactorial etiology of recurrent miscarriage and its scientific and clinical implications. Gynecol. Obstet. Investig. 2008;66:257–267. doi: 10.1159/000149575. PubMed DOI

Macklon N.S., Geraedts J.P., Fauser B.C. Conception to ongoing pregnancy: The ‘black box’ of early pregnancy loss. Hum. Reprod. Update. 2002;8:333–343. doi: 10.1093/humupd/8.4.333. PubMed DOI

Tavares Da Silva F., Gonik B., McMillan M., Keech C., Dellicour S., Bhange S., Tila M., Harper D.M., Woods C., Kawai A.T., et al. Stillbirth: Case definition and guidelines for data collection, analysis, and presentation of maternal immunization safety data. Vaccine. 2016;34:6057–6068. doi: 10.1016/j.vaccine.2016.03.044. PubMed DOI PMC

Management of stillbirth ACOG Obstetric Care Consensus No. 10. American College of Obstetricians and Gynecologists. Obstet. Gynecol. 2020;135:e110–e132. PubMed

MacDorman M.F., Gregory E.C. Fetal and Perinatal Mortality: United States, 2013. Natl. Vital. Stat. Rep. 2015;64:1–24. PubMed

Smith G.C., Fretts R.C. Stillbirth. Lancet. 2007;370:1715–1725. doi: 10.1016/S0140-6736(07)61723-1. PubMed DOI

Lawn J.E., Blencowe H., Pattinson R., Cousens S., Kumar R., Ibiebele I., Gardosi J., Day L.T., Stanton C., Lancet’s Stillbirths Series steering committee Stillbirths: Where? When? Why? How to make the data count? Lancet. 2011;377:1448–1463. doi: 10.1016/S0140-6736(10)62187-3. PubMed DOI

Monteiro L.J., Varas-Godoy M., Acuña-Gallardo S., Correa P., Passalacqua G., Monckeberg M., Rice G.E., Illanes S.E. Increased Circulating Levels of Tissue-Type Plasminogen Activator Are Associated with the Risk of Spontaneous Abortion during the First Trimester of Pregnancy. Diagnostics. 2020;10:197. doi: 10.3390/diagnostics10040197. PubMed DOI PMC

Deng W., Sun R., Du J., Wu X., Ma L., Wang M., Lv Q. Prediction of miscarriage in first trimester by serum estradiol, progesterone and β-human chorionic gonadotropin within 9 weeks of gestation. BMC Pregnancy Childbirth. 2022;22:112. doi: 10.1186/s12884-021-04158-w. PubMed DOI PMC

Jiang L., Du Y., Lu Y., Wu X., Tong X. Monitoring of hemostatic parameters for early prediction of first-trimester miscarriage. Biomarkers. 2021;26:532–538. doi: 10.1080/1354750X.2021.1933592. PubMed DOI

Bahado-Singh R.O., Syngelaki A., Mandal R., Han B., Li L., Bjorndahl T.C., Wang N., Maulik D., Dong E., Turkoglu O., et al. First-trimester metabolomic prediction of stillbirth. J. Matern. Fetal Neonatal Med. 2019;32:3435–3441. doi: 10.1080/14767058.2018.1465552. PubMed DOI

Kleinrouweler C.E., Cheong-See F.M., Collins G.S., Kwee A., Thangaratinam S., Khan K.S., Mol B.W., Pajkrt E., Moons K.G., Schuit E. Prognostic models in obstetrics: Available, but far from applicable. Am. J. Obstet. Gynecol. 2016;214:79–90.e36. doi: 10.1016/j.ajog.2015.06.013. PubMed DOI

Conde-Agudelo A., Bird S., Kennedy S.H., Villar J., Papageorghiou A.T. First- and second-trimester tests to predict stillbirth in unselected pregnant women: A systematic review and meta-analysis. BJOG. 2015;122:41–55. doi: 10.1111/1471-0528.13096. PubMed DOI

Åmark H., Westgren M., Persson M. Prediction of stillbirth in women with overweight or obesity-A register-based cohort study. PLoS ONE. 2018;13:e0206940. doi: 10.1371/journal.pone.0206940. PubMed DOI PMC

Akolekar R., Machuca M., Mendes M., Paschos V., Nicolaides K.H. Prediction of stillbirth from placental growth factor at 11–13 weeks. Ultrasound Obstet. Gynecol. 2016;48:618–623. doi: 10.1002/uog.17288. PubMed DOI

Akolekar R., Bower S., Flack N., Bilardo C.M., Nicolaides K.H. Prediction of miscarriage and stillbirth at 11–13 weeks and the contribution of chorionic villus sampling. Prenat. Diagn. 2011;31:38–45. doi: 10.1002/pd.2644. PubMed DOI

Mastrodima S., Akolekar R., Yerlikaya G., Tzelepis T., Nicolaides K.H. Prediction of stillbirth from biochemical and biophysical markers at 11–13 weeks. Ultrasound Obstet. Gynecol. 2016;48:613–617. doi: 10.1002/uog.17289. PubMed DOI

Townsend R., Manji A., Allotey J., Heazell A., Jorgensen L., Magee L.A., Mol B.W., Snell K., Riley R.D., Sandall J., et al. Can risk prediction models help us individualise stillbirth prevention? A systematic review and critical appraisal of published risk models. BJOG. 2021;128:214–224. doi: 10.1111/1471-0528.16487. PubMed DOI

Bottomley C., Van Belle V., Kirk E., Van Huffel S., Timmerman D., Bourne T. Accurate prediction of pregnancy viability by means of a simple scoring system. Hum. Reprod. 2013;28:68–76. doi: 10.1093/humrep/des352. PubMed DOI

Guha S., Van Belle V., Bottomley C., Preisler J., Vathanan V., Sayasneh A., Stalder C., Timmerman D., Bourne T. External validation of models and simple scoring systems to predict miscarriage in intrauterine pregnancies of uncertain viability. Hum. Reprod. 2013;28:2905–2911. doi: 10.1093/humrep/det342. PubMed DOI

Wan O.Y.K., Chan S.S.C., Chung J.P.W., Kwok J.W.K., Lao T.T.H., Sahota D.S. External validation of a simple scoring system to predict pregnancy viability in women presenting to an early pregnancy assessment clinic. Hong Kong Med. J. 2020;26:102–110. doi: 10.12809/hkmj198276. PubMed DOI

Ashoor G., Syngelaki A., Papastefanou I., Nicolaides K.H., Akolekar R. Development and validation of model for prediction of placental dysfunction-related stillbirth from maternal factors, fetal weight and uterine artery Doppler at mid-gestation. Ultrasound Obstet. Gynecol. 2022;59:61–68. doi: 10.1002/uog.24795. PubMed DOI

Hromadnikova I., Kotlabova K., Krofta L. Cardiovascular Disease-Associated MicroRNA Dysregulation during the First Trimester of Gestation in Women with Chronic Hypertension and Normotensive Women Subsequently Developing Gestational Hypertension or Preeclampsia with or without Fetal Growth Restriction. Biomedicines. 2022;10:256. PubMed PMC

Hromadnikova I., Kotlabova K., Krofta L. First-Trimester Screening for HELLP Syndrome-Prediction Model Based on MicroRNA Biomarkers and Maternal Clinical Characteristics. Int. J. Mol. Sci. 2023;24:5177. doi: 10.3390/ijms24065177. PubMed DOI PMC

Hromadnikova I., Kotlabova K., Krofta L. First-Trimester Screening for Fetal Growth Restriction and Small-for-Gestational-Age Pregnancies without Preeclampsia Using Cardiovascular Disease-Associated MicroRNA Biomarkers. Biomedicines. 2022;10:718. doi: 10.3390/biomedicines10030718. PubMed DOI PMC

Hromadnikova I., Kotlabova K., Krofta L. First Trimester Prediction of Preterm Delivery in the Absence of Other Pregnancy-Related Complications Using Cardiovascular-Disease Associated MicroRNA Biomarkers. Int. J. Mol. Sci. 2022;23:3951. doi: 10.3390/ijms23073951. PubMed DOI PMC

Hromadnikova I., Kotlabova K., Krofta L. Cardiovascular Disease-Associated MicroRNAs as Novel Biomarkers of First-Trimester Screening for Gestational Diabetes Mellitus in the Absence of Other Pregnancy-Related Complications. Int. J. Mol. Sci. 2022;23:10635. doi: 10.3390/ijms231810635. PubMed DOI PMC

The Fetal Medicine Foundation Stratification of Pregnancy Management 11–13 Weeks’ Gestation. [(accessed on 4 February 2023)]. Available online: https://courses.fetalmedicine.com/research/assess/

Fretts R.C., Schmittdiel J., McLean F.H., Usher R.H., Goldman M.B. Increased maternal age and the risk of fetal death. N. Engl. J. Med. 1995;333:953–957. doi: 10.1056/NEJM199510123331501. PubMed DOI

Reddy U.M., Ko C.W., Willinger M. Maternal age and the risk of stillbirth throughout pregnancy in the United States. Am. J. Obstet. Gynecol. 2006;195:764–770. doi: 10.1016/j.ajog.2006.06.019. PubMed DOI

Catalano P.M. Management of obesity in pregnancy. Obstet. Gynecol. 2007;109:419–433. doi: 10.1097/01.AOG.0000253311.44696.85. PubMed DOI

Flenady V., Koopmans L., Middleton P., Frøen J.F., Smith G.C., Gibbons K., Coory M., Gordon A., Ellwood D., McIntyre H.D., et al. Major risk factors for stillbirth in high-income countries: A systematic review and meta-analysis. Lancet. 2011;377:1331–1340. doi: 10.1016/S0140-6736(10)62233-7. PubMed DOI

Aune D., Saugstad O.D., Henriksen T., Tonstad S. Maternal body mass index and the risk of fetal death, stillbirth, and infant death: A systematic review and meta-analysis. JAMA. 2014;311:1536–1546. doi: 10.1001/jama.2014.2269. PubMed DOI

Marufu T.C., Ahankari A., Coleman T., Lewis S. Maternal smoking and the risk of still birth: Systematic review and meta-analysis. BMC Public Health. 2015;15:239. doi: 10.1186/s12889-015-1552-5. PubMed DOI PMC

Stillbirth Collaborative Research Network Writing Group Association between stillbirth and risk factors known at pregnancy confirmation. JAMA. 2011;306:2469–2479. doi: 10.1001/jama.2011.1798. PubMed DOI PMC

Jackson R.A., Gibson K.A., Wu Y.W., Croughan M.S. Perinatal outcomes in singletons following in vitro fertilization: A meta-analysis. Obstet. Gynecol. 2004;103:551–563. doi: 10.1097/01.AOG.0000114989.84822.51. PubMed DOI

Marino J.L., Moore V.M., Willson K.J., Rumbold A., Whitrow M.J., Giles L.C., Davies M.J. Perinatal outcomes by mode of assisted conception and sub-fertility in an Australian data linkage cohort. PLoS ONE. 2014;9:e80398. doi: 10.1371/journal.pone.0080398. PubMed DOI PMC

Wisborg K., Ingerslev H.J., Henriksen T.B. IVF and stillbirth: A prospective follow-up study. Hum. Reprod. 2010;25:1312–1316. doi: 10.1093/humrep/deq023. PubMed DOI

Bay B., Lyngsø J., Hohwü L., Kesmodel U.S. Childhood growth of singletons conceived following in vitro fertilisation or intracytoplasmic sperm injection: A systematic review and meta-analysis. BJOG. 2019;126:158–166. doi: 10.1111/1471-0528.15456. PubMed DOI

Merritt T.A., Goldstein M., Philips R., Peverini R., Iwakoshi J., Rodriguez A., Oshiro B. Impact of ART on pregnancies in California: An analysis of maternity outcomes and insights into the added burden of neonatal intensive care. J. Perinatol. 2014;34:345–350. doi: 10.1038/jp.2014.17. PubMed DOI

Lamont K., Scott N.W., Jones G.T., Bhattacharya S. Risk of recurrent stillbirth: Systematic review and meta-analysis. BMJ. 2015;350:h3080. doi: 10.1136/bmj.h3080. PubMed DOI

Hartmann K.E., Velez Edwards D.R., Savitz D.A., Jonsson-Funk M.L., Wu P., Sundermann A.C., Baird D.D. Prospective Cohort Study of Uterine Fibroids and Miscarriage Risk. Am. J. Epidemiol. 2017;186:1140–1148. doi: 10.1093/aje/kwx062. PubMed DOI PMC

Lai J., Caughey A.B., Qidwai G.I., Jacoby A.F. Neonatal outcomes in women with sonographically identified uterine leiomyomata. J. Matern. Fetal Neonatal Med. 2012;25:710–713. doi: 10.3109/14767058.2011.572205. PubMed DOI

Shavell V.I., Thakur M., Sawant A., Kruger M.L., Jones T.B., Singh M., Puscheck E.E., Diamond M.P. Adverse obstetric outcomes associated with sonographically identified large uterine fibroids. Fertil. Steril. 2012;97:107–110. doi: 10.1016/j.fertnstert.2011.10.009. PubMed DOI

Hosseinirad H., Yadegari P., Falahieh F.M., Shahrestanaki J.K., Karimi B., Afsharzadeh N., Sadeghi Y. The impact of congenital uterine abnormalities on pregnancy and fertility: A literature review. JBRA Assist. Reprod. 2021;25:608–616. doi: 10.5935/1518-0557.20210021. PubMed DOI PMC

Drakeley A.J., Quenby S., Farquharson R.G. Mid-trimester loss--appraisal of a screening protocol. Hum. Reprod. 1998;13:1975–1980. doi: 10.1093/humrep/13.7.1975. PubMed DOI

Alexander E.K., Pearce E.N., Brent G.A., Brown R.S., Chen H., Dosiou C., Grobman W.A., Laurberg P., Lazarus J.H., Mandel S.J., et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid. 2017;27:315–389. doi: 10.1089/thy.2016.0457. PubMed DOI

De Vivo A., Mancuso A., Giacobbe A., Moleti M., Maggio Savasta L., De Dominici R., Priolo A.M., Vermiglio F. Thyroid function in women found to have early pregnancy loss. Thyroid. 2010;20:633–637. doi: 10.1089/thy.2009.0323. PubMed DOI

Stagnaro-Green A., Roman S.H., Cobin R.H., el-Harazy E., Alvarez-Marfany M., Davies T.F. Detection of at-risk pregnancy by means of highly sensitive assays for thyroid autoantibodies. JAMA. 1990;264:1422–1425. doi: 10.1001/jama.1990.03450110068029. PubMed DOI

Chen L., Hu R. Thyroid autoimmunity and miscarriage: A meta-analysis. Clin. Endocrinol. 2011;74:513–519. doi: 10.1111/j.1365-2265.2010.03974.x. PubMed DOI

Thangaratinam S., Tan A., Knox E., Kilby M.D., Franklyn J., Coomarasamy A. Association between thyroid autoantibodies and miscarriage and preterm birth: Meta-analysis of evidence. BMJ. 2011;342:d2616. doi: 10.1136/bmj.d2616. PubMed DOI PMC

Practice bulletin no. 124: Inherited thrombophilias in pregnancy. Obstet. Gynecol. 2011;118:730–740. PubMed

Bates S.M., Greer I.A., Middeldorp S., Veenstra D.L., Prabulos A.M., Vandvik P.O. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e691S–e736S. doi: 10.1378/chest.11-2300. PubMed DOI PMC

Marik P.E., Plante L.A. Venous thromboembolic disease and pregnancy. N. Engl. J. Med. 2008;359:2025–2033. doi: 10.1056/NEJMra0707993. PubMed DOI

Tian Q.X., Xia S.H., Wu Y.H., Zhang J.H., Wang L.Y., Zhu W.P. Comprehensive analysis of the differential expression profile of microRNAs in missed abortion. Kaohsiung J. Med. Sci. 2020;36:114–121. doi: 10.1002/kjm2.12144. PubMed DOI PMC

Hosseini M.K., Gunel T., Gumusoglu E., Benian A., Aydinli K. MicroRNA expression profiling in placenta and maternal plasma in early pregnancy loss. Mol. Med. Rep. 2018;17:4941–4952. doi: 10.3892/mmr.2018.8530. PubMed DOI PMC

Winger E.E., Reed J.L., Ji X. First-trimester maternal cell microRNA is a superior pregnancy marker to immunological testing for predicting adverse pregnancy outcome. J. Reprod. Immunol. 2015;110:22–35. doi: 10.1016/j.jri.2015.03.005. PubMed DOI

Shahidi M., Nazari F., Ghanbarian H., Taheripanah R., Hajivalili M., Amani D. miR-146b-5p and miR-520h Expressions Are Upregulated in Serum of Women with Recurrent Spontaneous Abortion. Biochem. Genet. 2022;60:1716–1732. doi: 10.1007/s10528-021-10173-5. PubMed DOI

Zhao L., Han L., Hei G., Wei R., Zhang Z., Zhu X., Guo Q., Chu C., Fu X., Xu K., et al. Diminished miR-374c-5p negatively regulates IL (interleukin)-6 in unexplained recurrent spontaneous abortion. J. Mol. Med. 2022;100:1043–1056. doi: 10.1007/s00109-022-02178-3. PubMed DOI

Tutunfroush M., Ghorbian S., Mohseni J., Danaii S., Rad M.G. Down-Regulation of circulating miR-23a-3p, miR-101-3p, and miR-let-7c in Women with Idiopathic Recurrent Pregnancy Loss. Clin. Lab. 2022;68 doi: 10.7754/Clin.Lab.2022.211142. PubMed DOI

Abbaskhani H., Seifati S.M., Salmani T., Vojdani S., Al-Rubaye S., Yaseen R., Hajiesmaeili Y., Ghaderian S.M.H. Evaluating changes in the expression of BCL-2 gene, lncRNA SRA, and miR-361-3p in unexplained recurrent pregnancy loss. Nucleosides Nucleotides Nucleic Acids. 2022;41:891–899. doi: 10.1080/15257770.2022.2085298. PubMed DOI

Qin W., Tang Y., Yang N., Wei X., Wu J. Potential role of circulating microRNAs as a biomarker for unexplained recurrent spontaneous abortion. Fertil. Steril. 2016;105:1247–1254.e3. doi: 10.1016/j.fertnstert.2016.01.028. PubMed DOI

Cho S.H., Kim J.H., An H.J., Kim Y.R., Ahn E.H., Lee J.R., Kim J.O., Ko J.J., Kim N.K. Genetic Polymorphisms in miR-604A>G, miR-938G>A, miR-1302-3C>T and the Risk of Idiopathic Recurrent Pregnancy Loss. Int. J. Mol. Sci. 2021;22:6127. doi: 10.3390/ijms22116127. PubMed DOI PMC

Al-Rubaye S., Ghaderian S.M.H., Salehpour S., Salmani T., Vojdani S., Yaseen R., Akbarzadeh R. Aberrant expression of BAX, MEG3, and miR-214-3P genes in recurrent pregnancy loss. Gynecol. Endocrinol. 2021;37:660–664. doi: 10.1080/09513590.2021.1897098. PubMed DOI

Yang Q., Gu W.W., Gu Y., Yan N.N., Mao Y.Y., Zhen X.X., Wang J.M., Yang J., Shi H.J., Zhang X., et al. Association of the peripheral blood levels of circulating microRNAs with both recurrent miscarriage and the outcomes of embryo transfer in an in vitro fertilization process. J. Transl. Med. 2018;16:186. doi: 10.1186/s12967-018-1556-x. PubMed DOI PMC

Jairajpuri D.S., Malalla Z.H., Mahmood N., Khan F., Almawi W.Y. Differentially expressed circulating microRNAs associated with idiopathic recurrent pregnancy loss. Gene. 2021;768:145334. doi: 10.1016/j.gene.2020.145334. PubMed DOI

Ding J., Zhang Y., Cai X., Zhang Y., Yan S., Wang J., Zhang S., Yin T., Yang C., Yang J. Extracellular vesicles derived from M1 macrophages deliver miR-146a-5p and miR-146b-5p to suppress trophoblast migration and invasion by targeting TRAF6 in recurrent spontaneous abortion. Theranostics. 2021;11:5813–5830. doi: 10.7150/thno.58731. PubMed DOI PMC

Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–408. doi: 10.1006/meth.2001.1262. PubMed DOI

Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., Speleman F. Accurate normalization of re-al-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3:RESEARCH0034. doi: 10.1186/gb-2002-3-7-research0034. PubMed DOI PMC

Hromadnikova I., Kotlabova K., Hympanova L., Krofta L. Gestational hypertension, preeclampsia and intrauterine growth restriction induce dysregulation of cardiovascular and cerebrovascular disease associated microRNAs in maternal whole peripher-al blood. Thromb. Res. 2016;137:126–140. doi: 10.1016/j.thromres.2015.11.032. PubMed DOI

Benjamini Y., Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B. 1995;57:289–300. doi: 10.1111/j.2517-6161.1995.tb02031.x. DOI

Abnormal microRNA expression profile at early stages of gestation in pregnancies destined to develop placenta previa

First-trimester predictive models for adverse pregnancy outcomes-a base for implementation of strategies to prevent cardiovascular disease development

Special Issue of Pathogenesis of Pregnancy-Related Complications, 2023